Covid-19: Eli Lilly’s monoclonal antibody already highly contested

DECRYPTION – The evidence for the effectiveness of bamlanivimab is considered far too fragile by some specialists.

Was it necessary, yes or no, to urgently give a temporary authorization for use (ATU) to Eli Lilly’s bamlanivimab in view of the existing data on this experimental treatment against Covid? The debate did not fail to bloom after the Minister of Health, Olivier Véran, announced last week the purchase of “tens of thousands of dosesTo the American pharmaceutical group and the opening of this treatment to over 80s and to immunocompromised people, the most vulnerable to the virus. The purchase price was not disclosed, but it would be a priori between 1000 and 2000 euros per dose, which also fuels the suspicions, more or less founded, of conflicts of interest.

In the absence of viral decay, I do not see what to expect from it. It’s like building a house on sand!

Mathieu Molimard, head of department at Bordeaux University Hospital

What about the effectiveness of this treatment, which must be administered intravenously in the hospital? So far, only two studies have been published, one in the New England Journal of Medicine and the other in Jama. They were published online on October 28 and January 21, respectively, but bear

This article is for subscribers only. You have 75% left to discover.

Subscribe: 1 € the first month

Cancellable at any time

Already subscribed? Log in


Leave a Reply

Your email address will not be published. Required fields are marked *